Designing success into your Life Sciences venture
Latest News: Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
We are a life sciences accelerator that collaborates with entrepreneurs, scientific founders and first-time CEOs to drive the successful development of their technologies to enable new treatment options for patients with serious disease. We offer our experienced team and deep network of industry consultants and service providers along with seed investment capital across a variety of technologies, including therapeutics, diagnostics, and devices with the singular goal of shepherding each program through a compelling clinical proof-of-concept study.
What we offer
We are a life sciences accelerator that collaborates with entrepreneurs, scientific founders and first-time CEOs to drive the successful development of their technologies to enable new treatment options for patients with serious disease. We offer our experienced team and deep network of industry consultants and service providers along with seed investment capital across a variety of technologies, including therapeutics, diagnostics, and devices with the singular goal of shepherding each program through a compelling clinical proof-of-concept study.
Collaborate
We believe in the spirit of collaboration, working with smart people, to foster creative solutions in achieving key milestones for the purpose of accelerating the advancement of new technologies. Join our network in this mission and help shape the future of our industry.
Who we are
Xontogeny’s team has scientific, business, operations and investment experience. Through the efforts of the team, Xontogeny supports and stays connected with its larger community of researchers and their institutions, pharmaceutical companies, investors, entrepreneurs, domain experts and other relevant industry organizations.
Portfolio​
Xontogeny has made a number of seed investments and continues to incubate a pipeline of early-stage life sciences companies across a wide variety of modalities and therapeutic areas.
